In a recent decision of Düsseldorf Local Division (UPC) in the case UPC_CFI_505/2024, both the revocation and infringement actions have been dismissed. This case raises important methodologies and perspectives regarding how to handle infringement of second medical use claims where allegedly infringing product is launched with a therapeutical indication (Section 4.1 of SmPC) not falling...
The Enlarged Board of Appeal of the European Patent Office (EPO) has received a new referral under the case number G 2/24 (“Skin cleanser”), addressing a critical procedural issue in European patent law: the legal status and procedural rights of third-party interveners in appeal proceedings after the withdrawal of all pending appeals. In decision T...
Federal Circuit Revives Amarin’s Induced Infringement Case Against Hikma Over Vascepa® Generic* In a significant decision for pharmaceutical patent litigation, the U.S. Court of Appeals for the Federal Circuit has reinstated Amarin Pharma’s lawsuit against Hikma Pharmaceuticals. The court found that Amarin had plausibly alleged Hikma’s conduct induced infringement of patents tied to the cardiovascular...
EPO has changed its fee strategy and started to apply fee reductions as of 01.04.2024. By decision of the Administrative Council of the European Patent Organisation dated 14 December 2023 (CA/ D 16/23), the EPO introduced a new fee scheme and new rules pertaining to fee reductions for certain applicants. New changes can be...
The EPO has announced in OJ EPO 2024, A41 that filing patent applications and other documents by facsimile shall be abolished as of 1 July, 2024. Any transmission of a patent application or other document by fax to the European Patent Office as of the above date shall be deemed not to have been received....
IP specialized law firm where a dynamic and learning team combines knowledge and experience to create the relevant IP asset for clients.
Invokat © 2025, All Rights Reserved
